- NCIt
- C4521
Loading cancer entity…
Loading cancer entity…
Clinical trials
11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer | terminated | N/A | 409 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05931354 | Longitudinal HPV Pap in CIN and VAIN(LHPCV) | unknown | — | 600 | Chang Gung Memorial HospitalOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04704908 |
Data updated 22 days agoSource updated Jul 14, 2025source: clinicaltrials
| Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) |
| unknown |
| — |
| 979 |
| Jun ZhangOTHER |
| 1 |
| Jan 26, 2023 |
| clinicaltrials |
| NCT04969445 | The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 647 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05045755 | The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 1,339 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05536843 | Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests(TTMV HPV DNA) | unknown | — | 500 | University of Mississippi Medical CenterOTHER | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05426148 | Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female | completed | Phase 4 | 540 | Xiamen Innovax Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT01735006 | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine | completed | Phase 3 | 7,372 | Xiamen UniversityOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03206255 | Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls | completed | — | 940 | Jun ZhangOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02562508 | A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls | completed | Phase 3 | 979 | Jun ZhangOTHER | 1 | Aug 16, 2018 | clinicaltrials |